UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 27, 2006
AVI BioPharma, Inc.
(Exact name of Company as specified in its charter)
Oregon |
|
0-22613 |
|
93-0797222 |
(State or other |
|
(Commission File No.) |
|
(I.R.S. Employer |
One S.W.
Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrants telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement
AVI BioPharma, Inc. (Nasdaq: AVII) (AVI), on January 27, 2006 announced that it had entered into a definitive License Agreement with Chiron Corporation (Chiron) granting AVI a nonexclusive license to Chirons patents and patent applications for the research, development, and commercialization of antisense therapeutics against hepatitis C virus (HCV), in exchange for the payment of certain milestone and royalty payments to Chiron.
In lieu of the first milestone payment due under the License Agreement, AVI and Chiron also entered into a separate agreement under which AVI issued to Chiron 89,012 shares of AVIs common stock. The agreement contains certain sales volume restrictions that encourage Chiron to sell the shares over a 60 day period following receipt of the shares. The agreement contains provisions to limit the gain Chiron will receive upon the sale of such shares. The agreement also contains customary representations and warranties and undertakings regarding the securities issued by AVI. AVI believes that Chiron will dispose of the shares in the open market over the next 60 days.
The common stock was issued pursuant to AVIs effective shelf registration statement.
A copy of AVIs press release concerning the License Agreement is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 7.01 Regulation FD Disclosure
The information set forth above is incorporated by reference herein.
Item 8.01 Other Events
The information set forth above is incorporated by reference herein.
Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
99.1 Press Release, dated January 27, 2006.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on February 1, 2006.
|
AVI BioPharma, Inc. |
||
|
|
||
|
By: |
/s/ ALAN P. TIMMINS |
|
|
|
|
|
|
|
Alan P. Timmins |
|
|
|
President and Chief Operating Officer |
|
|
|
(Principal Operating Officer) |
EXHIBIT INDEX
|
Document Description |
|
|
|
|
99.1 |
|
Press Release, dated January 27, 2006. |
2
Exhibit 99.1
For Immediate Release
AVI BioPharma Announces Hepatitis C Virus License Agreement With Chiron
AVI Contact:
AVI BioPharma, Inc.
Michael Hubbard (hubbard@avibio.com)
(503) 227-0554
Investor Contacts:
Lippert/Heilshorn & Associates Inc.
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
(310) 691-7100
Press Contact:
Waggener Edstrom Worldwide
Bioscience and Healthcare Practice
Jenny Moede (jmoede@WaggenerEdstrom.com)
(503) 443-7000
PORTLAND, Ore. Jan. 27, 2006 AVI BioPharma, Inc. (Nasdaq: AVII), today announced that it has entered into an agreement with Chiron Corp. granting AVI a nonexclusive license to Chirons patents and patent applications for the research, development and commercialization of antisense therapeutics against hepatitis C virus (HCV). Chiron scientists were the first to clone HCV, and the company has been granted more than 100 HCVrelated patents.
The license further strengthens AVIs patent position on its HCV antisense product candidates, which are already covered by issued U.S. patent claims. AVIs lead NeuGene® antisense compound for HCV, AVI4065, is currently being evaluated in a multicenter exploratory safety and efficacy clinical trial in the U.S. In conjunction with the license agreement, AVI will issue Chiron shares of AVI common stock as an initial license fee payment. Other financial terms of the agreement were not disclosed.
This agreement with Chiron positions AVI to move forward in our HCV development program with confidence and clarity around intellectual property, said Denis R. Burger, Ph.D., chief executive officer of AVI. The addition of the HCV patents licensed from Chiron to AVIs own patents provides a solid proprietary base in the HCV field for AVI and our eventual commercial partners.
The multicenter clinical study currently underway is designed to assess the safety, tolerability, pharmacokinetics and viral response to daily subcutaneous administration of AVI4065 among healthy volunteers and patients with chronic active HCV. AVI recently reported completion of the first phase of this study with favorable safety, tolerability and pharmacokinetic profiles and is now in the second efficacy phase of the program. Additional data are expected from this trial later in the first quarter.
1
The principal investigator of the clinical trial is Mark Holodniy, M.D., F.A.C.P., professor of medicine at Stanford University School of Medicine and director of the Department of Veterans Affairs Public Health Research & Consultation Program.
About Hepatitis C
Chronic HCV infection causes an inflammation of the liver that can result in the development of cirrhosis, liver cancer or liver failure. According to the World Health Organization, approximately 170 million people worldwide are chronically infected with HCV. It is the most common chronic bloodborne infection in the developed world and the leading cause of liver transplants in the U.S. The CDC estimates that approximately 3.9 million Americans have been infected with HCV, of whom 2.7 million are chronically infected.
The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCVrelated cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which makes it difficult for almost half of initially treated patients to tolerate the recommended dosages and duration of treatment.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of lifethreatening diseases using thirdgeneration NeuGene antisense drugs. AVIs lead NeuGene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVIs antiviral program uses NeuGene antisense compounds to combat disease by targeting singlestranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus and Ebola virus. AVI has introduced a NeuGenebased exonskipping technology called ESPRIT therapy. More information about AVI is available on the companys Web site at www.avibio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forwardlooking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the companys Securities and Exchange Commission filings.
2